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Abstract
Plasmonics-active gold nanostars exhibiting strong imaging contrast and efficient photothermal 
transduction were synthesized for a novel pulsed laser-modulated plasmonics-enhanced brain 
tumor microvascular permeabilization. We demonstrate a selective, optically modulated delivery 
of nanoprobes into the tumor parenchyma with minimal off-target distribution.
In the pursuit of better treating medically intractable malignant glioblastoma, novel 
strategies designed to overcome the physiological obstacles imposed by the blood brain-
tumor barrier (BBTB) have been shown to facilitate the delivery of therapeutic agents into 
the tumor parenchyma.1, 2 Strategies exploiting either biological entities (e.g., 
immunotherapy, gene therapy) or transient physical blood-brain barrier (BBB) disruption 
(e.g., high-intensity focused ultrasound [HIFU]) have recently shown significant preclinical 
progress.3, 4 Novel platforms based on nanotechnology have also emerged to treat 
neurological malignancies due to their superior pharmacokinetic profiles than conventional 
drugs.5, 6 Targeted brain tumor nano-drug delivery can be achieved by exploiting their 
enhanced permeation and retention (EPR) effect as well as utilizing them as molecular 
“Trojan horses” (e.g., receptor-mediated transcytosis via transferrin, apolipoprotein, cyclic-
RGD peptide, etc.). However, prior efforts have shown that with nano-drugs alone, the 
majority of systemically injected nanoparticles (NPs) remain in the reticuloendothelial 
system (RES; e.g., liver, spleen, lymph node, etc.) whereas brain accumulation accounts for 
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less than 0.1 % of the injection dosage.7, 8 Here, we develop a new strategy to increase the 
brain tumor accumulation by integrating nanotechnology (e.g. theranostics, targeted 
delivery) with selective BBTB permeation. We demonstrate that such strategy not only 
allows for nano-drug imaging and therapeutic response monitoring, but also induces 
transient BBTB permeation for use in enhanced nano-drug delivery with superior spatial and 
temporal specificity. As a result, image-guided BBTB permeabilization and controlled nano-
drug delivery are achieved and will bring new insights to targeted brain tumor therapy.
Our strategy involves developing novel monolithic multifunctional NPs that features three 
functionalities: optical imaging contrast, photoactivated transducer, and therapeutic agent. 
Unlike three separated agents with distinct pharmakokinetic profiles, integrated design 
exhibits shared pharmacokinetic profile suitable for direct monitoring the delivery of 
therapeutic agent. Compared to conventional imaging methods (e.g., MRI or ultrasound), 
optical methods also offer higher spatial and temporal resolution.9 Hence, such an optical 
theranostic NP can be imaged and photoactivated under a single optical setup in high 
resolution.
In this study, NIR-responsive plasmonic gold nanostars (GNS) were used. Recently, NIR-
responsive plasmonic gold NPs of various shapes (e.g., shell, rod, cage, hollow sphere, star, 
etc.) have become one of the most promising theranostic agents designed for preclinical 
optical imaging and therapeutics.10-13 Also, plasmonic gold NPs exhibit simple size/shape 
tunability, versatile surface chemistry, intrinsic optical property, and biocompatibility. 
Depending on their nanoscale sizes and shapes, they display strongly enhanced 
electromagnetic fields due to the so-called ‘plasmonic effect’, which produces unique 
intrinsic optical properties that can be exploited as imaging contrast and therapeutic agents 
without further coupling of dye or drug.10, 12
In particular, GNS not only have plasmon peaks in the NIR ‘tissue optical window’ range 
but also contain multiple sharp tips creating a “lightning rod” effect that further enhances the 
local surface plasmon; these unique optical properties bring forth strong surface-enhanced 
Raman scattering intensity (106 enhancement factor), large extinction coefficient (109-10 
M-1 cm-1), enhanced two-photon photoluminescence (two-photon action cross section of 106 
Goeppert-Mayer unit), and short lifetime (0.2 ns) for sensitive real-time imaging,14, 15 as 
well as efficient photothermal transduction for photothermal therapy or photothermal-
triggered drug release.16-18 With these unique plasmonic features, GNS are potential 
multifunctional plasmonic NPs that allow for both high-resolution imaging evaluation of NP 
intratumoral distribution and image-guided photothermal-triggered BBTB permeabilization 
for controlled NP delivery.10
Here, GNS' plasmon maximum was tuned to 800 nm to match the laser excitation system for 
optimal two-photon photoluminescence response (Fig. 1A). The GNS surface was protected 
by PEGylation for reduced RES clearance and extended circulatory half-life. The final 
hydrodynamic size was around 80 nm (Fig. S1). When investigated via photoacoustic 
computer tomography (PACT) through intact scalp,19 the photoacoustic (PA) signal rose 
instantly and then increased gradually before reaching a maximum at around half an hour 
(Fig. 1B). The intravascular PA intensity then slowly declined as GNS were cleared from 
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the RES or extravasated into tissues elsewhere. Measured through PACT, an extended 
circulatory half-life greater than 4 hours was found. Furthermore, due to its large extinction 
coefficient, high absorption-to-scattering ratio, and multiple thin branches favorable for heat 
generation, the GNS heat up quickly upon laser irradiation rendering it an efficient 
photothermal transducer (Fig. S1).20
To investigate the GNS intratumoral distribution with high spatial resolution, multiphoton 
microscopy (MPM) was employed through a cranial window chamber on orthotopic brain 
tumor animal models. Tumor xenograft in the cranium typically has smaller pore cutoff size 
than subcutaneous xenograft. Using dextran of various sizes, the pore size of the D270 
glioma xenograft was found around 70-100 kDa (7∼9 nm; data not shown), which is smaller 
than that of the commonly used U87MG glioma xenograft;21 D270 thus behaves closer than 
U87MG to actual human glioma. Due to GNS' intense two-photon photoluminescence signal 
and short fluorescence lifetime, subcellular resolution MPM imaging of GNS can be 
obtained using low laser energy (e.g., 0.5∼1.5 mW at 800 nm) and fast scanning speed (e.g., 
2 μs/pixel). Since standard biodistribution quantification on a whole brain using elemental 
analysis (e.g., ICP-MS) or whole-body imaging cannot distinguish intravascular or 
intraparenchymal accumulation, MPM complements whole-body imaging by offering a 
unique imaging tool with superior detection sensitivity and greater spatial/temporal 
resolution.
Fig. 1C illustrates a high-resolution depth-resolved in vivo cerebral microangiogram taken 
through a cranial window. Capillaries were clearly visible with minimal tissue 
autofluorescence background. Unlike commonly used intravascular contrast (e.g., FITC-
dextran) that undergoes significant signal decay in less than 30 minutes, the intravascular 
intensity of our GNS remained stable for hours without significant extravasation (Fig. S2), 
reflecting its intravascular stability inherited from inert gold and strong surface PEGylation. 
On a non-perfused mouse whole brain resected 3-hour post injection, GNS can be seen more 
prevalent in the tumor than the surrounding normal area (Fig. 1C,S3). On histology of 
perfused brains, GNS not only accumulated in the tumor vascular endothelial cells (ECs), 
but also selectively penetrated BBTB but minimally BBB to enter perivascular tumor 
parenchyma and tumor periphery (Fig. 1C,S4,S5). Tumor vessels appear larger in diameter 
but lower in density whereas distinctive GNS extravasation can be clearly seen. Long 
circulatory half-life superimposed on the EPR effect (fenestrated or gapped EC on capillary 
or venule) leads to EC accumulation and paracellular extravasation with possibly minimal 
true transcytosis.22 Peripheral tumor accumulation of PEG-GNS is most likely due to the 
hyper-neovascularity along the tumor edge and interstitial fluid pressure gradient at the 
boundary that would attenuate GNS delivery deep into the tumor. Nonetheless, a great 
portion of PEG-GNS still accumulated in RES (Fig. S6). To further enhance the brain tumor 
GNS delivery and reduce off-target distribution, additional BBTB opening mechanism needs 
to be explored.
To date, many alternative delivery strategies have been investigated for systemically 
delivering NPs into brain parenchyma.4, 23, 24 In particular, HIFU, which has been applied to 
increase BBB permeation by transiently disrupting the vascular integrity, has shown some 
progress in preclinical settings.25 To improve the delivery specificity from HIFU 
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(millimeter-resolution), optical method featuring superior spatial control (micrometer-
resolution) potentially allows for more specific delivery. Choi et al. recently reported 
optically modulated selective vascular permeabilization using a pulsed laser but required 
high laser power (300-2000 mW).26 To reduce the laser burden while maintaining the 
optical selectivity, plasmonics-active NPs can be used to significantly enhance the laser-
induced permeabilization effect. Ultrashort laser pulse interacting with plasmonics-active 
nanoparticles can lead to heating, stress wave release, or vapor bubble formation.27, 28 GNS, 
by having plasmon absorption matching the excitation laser, high absorption-to-scattering 
ratio, and multiple thin branches favorable for heat generation,20 can therefore be a strong 
candidate to enhance the laser-induced vascular permeabilization. Our study for the first 
time achieved a plasmonics-enhanced and optically modulated delivery of GNS into brain 
tumor under a much lower laser power (35 mW).
Exploiting GNS' plasmonic property, a locally triggered vascular permeabilization can be 
achieved through a cranial window in vivo at low NP dose (< 1 pmole) and laser power (35 
mW; 14 W/cm2) (Fig. 2), thus avoiding unwanted hemorrhagic infarction under high-power 
photothermal treatment (data not shown). The irradiation was performed within 10 minutes 
after PEG-GNS tail vein injection when most GNS were intravascular with little uptake in 
ECs or RES. After finding the tumor region, the laser irradiation was performed on the same 
multiphoton microscope. Immediately following the pulsed laser irradiation, some 
vasoconstriction and a minute focal extravasation was visible (Fig. 2B). 48-hour afterwards, 
extravasation could be seen in tumor vessels confined to the whole irradiated volume but not 
the surrounding tumor tissue (Fig. 2C-G). In normal brain, no apparent extravasation was 
found after the same irradiation (Fig. S7). Irradiating the brain tumor region using the same 
laser power but without GNS resulted in no observable extravasation of FITC-dextran (Fig. 
S8). The treatment was well tolerated with no sign of neurological disability over the next 2 
days. Even though the tumor vascular pore size is much smaller than the 80-nm GNS, an 
apparent GNS permeation of 10-30 μm deep into tumor parenchyma is visible (Fig. 2C-E); 
the extravasation depth is much greater than that from merely EPR effect. It is of interest 
that the selective tumor vessel response may add another level of tumor targeting specificity. 
Although the irradiation is depth-limited in this study, it provides an unprecedented spatial 
selectivity for enhanced targeted GNS delivery in cortical tumor.
To understand this process, it is noteworthy to know that the impact of NP exposure could 
be derived from a combined physical, chemical, as well as immunological trigger that 
eventually affect the BBB or BBTB causing increased vascular permeability. The 
mechanism of this delayed regional BBTB permeabilization may possibly explained by 
short-term intravascular hyperthermia or energy burst that triggers a local inflammatory 
response exacerbating the already weakened tumor neovasculature whereas normal vessels 
were less vulnerable and did not show significant extravasation.29 Hence, plasmonics-
enhanced low-energy pulsed laser treatment may preferentially induce tumor vascular ECs 
inflammasome activation that enhances regional BBTB permeability.
To investigate the possibility of the immunological involvement using an in vitro system, we 
examined the cytotoxicity and inflammasome induction on bone marrow derived 
macrophages (BMDMs) upon exposure to PEG-GNS. The formation of the NLRP3-
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inflammasome regulates the maturation of the proinflammatory cytokines (e.g., interleukin 
1β [IL-1β] and IL-18) in response to exogenous or endogenous danger signals during innate 
immunity. Here, PEG-GNS exposure to lipopolysaccharide (LPS)-primed macrophages 
resulted in the production of IL-1β and tumor necrosis factor α (TNFα) but not IL-6 (Fig. 3), 
implying that PEG-GNS do not induce a non-specific pan-inflammatory response. Rather, 
both TNFα and the inflammasome were activated related to NP concentration and 
incubation duration (Fig. S9); this is consistent with previous findings on different NPs (e.g., 
silica, silver, polystyrene) suggesting a possible universal immunological impact from 
NPs.30-32 Interestingly, although PEGylation can be used for reducing immunoclearance, 
PEGylated NP may still activate the inflammasome once being taken up a greater quantity 
by responsible cells. Meanwhile, unprimed macrophages showed no apparent cytotoxicity 
but induced a small secretion of IL-1β and IL-6 but greater secretion of TNFα at high PEG-
GNS concentration (10 nM). This finding is similar to the results by Trickler et al. where NP 
induced TNFα production in non-tumor rat brain microvessel ECs.33 It is possible that cells 
loaded with large dose of NPs may lead to reactive oxygen species (ROS) formation and 
cause lysosomal disruption.34 Lysosomal disruption is one signal that activates NLRP3 and 
this process has been implicated in signaling inflammasome activation in many reports 
where the trigger is nanomaterial.35 Nonetheless, although GNS exposure to “unprimed” 
macrophages did not alter cell viability, exposure to “primed” macrophages did decrease cell 
viability. It is therefore important to study the immunotoxicology profile before actual 
clinical applications.
Meanwhile, based on the response from primed macrophage, it is possible that exposing 
large dose NP to tumor neovasculature may exacerbate the already inflamed tumor 
microenvironment. Low-energy photothermal treatment, although may not induce cell death, 
has been shown to trigger the release of the danger-associated molecular patterns.36 
Combining the effect of NP exposure and photothermal treatment, it can potentially activate 
the inflammasome within tumor vascular ECs whereas the release of inflammatory 
cytokines may further enhance the EPR effect for deeper NP penetration. The exact 
mechanism on photothermally triggered BBTB permeabilization, however, requires further 
investigation.
Conclusion
This study demonstrates that plasmonics-active theranostic GNS can be a versatile 
nanoplatform for brain tumor imaging and controlled delivery of GNS into tumor in pre-
clinical settings. GNS could be delivered beyond the tumor vasculature and deep into the 
tumor parenchyma. By focusing ultrashort pulsed laser on brain tumor in mice preinjected 
with PEG-GNS, for the first time a proof-of-concept plasmonics-enhanced optically 
modulated image-guided brain tumor microvascular permeabilization was demonstrated, 
showing a highly spatial selective delivery of GNS into the tumor parenchyma with minimal 
off-target distribution. An immunological effect illustrated by inflammasome activation 
upon NP exposure may also contribute to the enhanced BBTB permeability. Based on these 
novel advances, we envision a strong translational potential on plasmonics-active theranostic 
gold nanostars for brain tumor molecular imaging and image-guided plasmonics-enhanced 
cancer therapy.
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(A) Plasmon band extinction spectrum and TEM image of GNS. Scale bar: 50 nm. (B) 
PACT image acquired through an intact mouse scalp after PEG-GNS injection. R: rostral 
rhinal vein. S: sagittal sinus. T: transverse sinus. Scale bar: 2 mm. PA intensity (normalized 
to the 1st frame) of sagittal sinus calculated from each frame. The small jerk at 600 second 
was due to system transition. (inset) Normalized PA intensity monitored for the initial 600 
seconds. (C) MPM imaging of cerebral microangiogram, Hoescht 33342-stained whole 
brain, and DAPI/CD31-stained histology. GNS are white. T: tumor. N: normal. Scale bar: 
200 μm.
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MPM images of photothermal-triggered tumor BBTB permeation examined through a 
cranial window. Tumor vessels prior to (A), 1-min after (B), and 48-hr after (C-G) laser 
irradiation. Following the irradiation, PEG-GNS (white) were found residing near the blood 
vessels and extravasating deep into the parenchyma (D,E), but not outside the irradiation 
zone (F,G). Red arrow denotes vascular tortuosity; red lines denote the border of irradiation. 
Scale bar: 100 μm.
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Cytokines induction (IL-1β [A], TNFα [B], IL-6 [C]), and cytotoxicity (D) profiles from 
LPS-primed and unprimed BMDMS treated with PEG-GNS for 24 hours. Triangles denote 
PEG-GNS concentration of roughly 10, 1, 0.1 nM. Error bar: 1 SD.
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